Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
s100a4 siRNA
- Development stage
- Preclinical
- Lead developer
- Cell Signaling Technology
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
S100A4 siRNA is a class of small interfering RNA (siRNA) research reagents designed to knock down the expression of the S100A4 gene (also known as metastasin or Mts1) through RNA interference (RNAi). S100A4 is a calcium-binding protein that is frequently overexpressed in highly metastatic cancers and is implicated in tumor invasion, angiogenesis, and metastasis. In research settings, S100A4 siRNA is used to study the role of this protein in various cancers, including pancreatic, hepatocellular, prostate, and lung cancers, as well as in fibrotic diseases and amyotrophic lateral sclerosis (ALS). While it is not an approved therapeutic drug, it is widely used as a laboratory tool, with commercial versions such as SignalSilence S100A4 siRNA produced by Cell Signaling Technology.
- Brand names
- SignalSilence S100A4 siRNA
- Other names
- S100A4 small interfering RNAS-100A4 small interfering RNAS 100A4 small interfering RNAmetastasin siRNAMts1 siRNAMts-1 siRNAMts 1 siRNA
02
Targets
S100 calcium-binding protein A4 (S100A4) mRNA
Beyond the preview
Go deeper on s100a4 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on s100a4 siRNA.